HC Wainwright Reiterates $34 Price Target on Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical stage oncology-focused company who is harnessing the power of Artificial Intelligence and Genomics to develop precision cancer therapies. By leveraging RADR®, Lantern's proprietary big data engine, more effective cancer treatments can be developed and delivered to the right group of patients at a faster rate and for a fraction of the cost. RADR® identifies genetic signature patterns that underpin the identification of patients for whom Lantern's portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. This is the future of precision medicine, and Lantern is at the forefront of AI driven transformation that will change the lives of cancer patients.

RADR®, Lantern’s AI platform now surpasses eight billion extensively curated and biologically relevant data points, more than 144 drug-cancer interactions, and over 85,500 patient records from 17 databases, including its own. The size and quality of RADR® is a unique competitive advantage for Lantern. It drives rapid identification of genetically defined biomarker signatures which are then used for precision oncology drug development, each of which can potentially be partnered for pivotal registration-directed trials, providing a clear and defined path for potential significant value creation for shareholders.

Lantern has two novel, highly potent molecules — LP-184 and LP-284 — with selective and differential activity in solid and liquid cancers. Lantern will present an abstract for LP-284 at the American Society of Hematology on Monday, December 13, 2021. LP-284’s potency was examined across 18 hematological cancer cells lines, and it was found that LP-284 showed potent activity in cell lines of acute lymphocytic leukemia, chronic myeloid leukemia, B-cell lymphoma, and Multiple Myeloma.

Recently, Michael G. King of H.C. Wainwright reiterated his Buy rating on Lantern Pharma with a price target of $34. As of November 8, Lantern closed at $10.17 and had a market cap of $113 million. Lantern is in a uniquely advantageous position to accelerate its development of LP-284 and partner with companies for synergistic therapies. H.C. Wainwright will continue to monitor LP-284’s target indicators into their models. The $34 price target was derived from the Monte Carlo simulation of 10,000 possible price target scenarios, equally weighing discounted cash flows (DCF), a residual income model (RIM), and the sum of the parts (SOTP).